ATTR amyloidosis silencer therapy uptake is transforming a previously underdiagnosed condition

Reading the signal

ATTR-CM is a form of heart failure caused by transthyretin amyloid deposition in cardiac tissue. It is more common than the historical clinical literature suggested, particularly in:

• Older patients with heart failure with preserved ejection fraction (HFpEF)
• Patients with hereditary TTR mutations (variant ATTR-CM)
• Patients with characteristic clinical features (carpal tunnel syndrome, lumbar spinal stenosis, low-voltage ECG patterns)

The diagnostic pathway has historically depended on cardiac scintigraphy (technetium pyrophosphate imaging) plus haematological assessment to rule out monoclonal gammopathy. Both are well-established but uneven in real-world implementation. The result has been substantial underdiagnosis, with patients receiving HFpEF management without ATTR-specific therapy.

The therapeutic class has expanded:

• TTR stabilisers (tafamidis, acoramidis) prevent transthyretin tetramer dissociation and amyloid formation
• TTR silencers (patisiran, vutrisiran, eplontersen) reduce hepatic transthyretin production through siRNA or ASO mechanisms
• Pipeline assets target adjacent mechanisms including amyloid clearance and TTR degradation

Real-world uptake of approved therapies is constrained primarily by the diagnostic pathway, not by the therapeutic class.

Commercial implications

For sponsors of ATTR-CM therapies and adjacent cardiomyopathy pipeline:

1. Diagnostic-pathway investment is the principal commercial lever. Cardiac scintigraphy capacity expansion, clinician awareness initiatives, and integration of ATTR-CM into HFpEF differential diagnosis pathways unlock the eligible population
2. The therapeutic-class differentiation conversation is now active. TTR silencers versus stabilisers, oral versus injection routes, and combination approaches are commercial-positioning axes
3. Adjacent cardiomyopathy indications (light-chain amyloidosis, hypertrophic cardiomyopathy, infiltrative cardiomyopathies) face the same diagnostic-pathway-dependent commercial environment

What we are watching

• Diagnostic pathway evolution and the rate of cardiac scintigraphy capacity expansion
• Combination protocol data testing TTR stabiliser plus silencer approaches
• Adjacent cardiomyopathy pipeline progress and how it inherits the ATTR-CM diagnostic infrastructure